Keyphrases
1-design
16%
Ability to Act
16%
Antigen-presenting Cells
16%
Antigen-specific Immune Response
33%
Antitumor Immune Response
16%
Cancer Immunotherapy
16%
Cancer Vaccine
66%
Cell-based
16%
Checkpoint Blockade
16%
Clinical Trials
16%
Co-functionalization
16%
Cytotoxic T-lymphocyte antigen-4 (CTLA-4)
16%
Disease Burden
16%
Effective Treatment
16%
FDA-approved Drugs
16%
Human Patients
16%
Immune Response
50%
Immuno-oncology
33%
Immunodeficient Mice
16%
Immunomodulatory Properties
16%
Immunostimulatory Oligonucleotides
33%
Immunotherapeutic Approaches
16%
Immunotherapeutics
33%
Median Overall Survival
16%
Median Progression-free Survival
16%
Medical Oncology
16%
Medical Surgery
16%
Metastatic Castration-resistant Prostate Cancer (mCRPC)
33%
Model Cell
16%
Mouse Model
16%
Multidisciplinary Team
16%
Nanoparticles
16%
Nanostructures
16%
Nanotechnology
16%
Nucleic Acid Technology
66%
Patient-derived Cell Line
16%
Patient-derived Models
16%
Potential Impact
16%
Programmed Death-ligand 1 (PD-L1)
16%
Prostate Cancer
66%
Prostate Cancer Cells
16%
Prostate-specific Antigen
100%
Recent Advances
16%
Scaleable
16%
Sipuleucel-T
16%
Specific Intent
16%
Spherical nucleic Acids
66%
Structural Features
16%
T Cell Activation
16%
Technology Structure
16%
Therapeutic Agents
16%
Therapeutic Vaccine
16%
Tumor Antigen
16%
Tumor Immunology
16%
Pharmacology, Toxicology and Pharmaceutical Science
Castration Resistant Prostate Cancer
33%
Clinical Trial
16%
Cytotoxic T Lymphocyte Antigen 4
16%
Disease
33%
Immunoglobulin
33%
Immunomodulating Agent
16%
Immunotherapy
33%
Malignant Neoplasm
16%
Mouse Model
33%
Nanomaterial
16%
Nanoparticle
16%
Neoplasm
16%
Nucleic Acid
66%
Oligonucleotide
33%
Overall Survival
16%
Progression Free Survival
16%
Prostate Cancer
83%
Prostate Specific Membrane Antigen
100%
Sipuleucel T
16%
Therapeutic Vaccine
16%
Tumor Antigen
16%
Tumor Model
16%
Tumor Vaccine
66%
Immunology and Microbiology
Antigen-Presenting Cell
16%
Cancer Cell
16%
Cell Activity
16%
Immune Response
100%
Immunology
33%
Immunomodulating Drugs
16%
Immunotherapy
33%
Intravenous Immunoglobulin
33%
Mouse Model
33%
Overall Survival
16%
Programmed Death-Ligand 1
16%
Progression Free Survival
16%
Prostate
50%
Prostate Specific Membrane Antigen
100%
Sipuleucel-T
16%
T Cell
16%
Tumor Antigen
16%
Tumor Immunology
16%
Tumor Vaccine
66%